Genor Biopharma Holdings (HKSE:06998) Total Current Assets : HK$1,139.5 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Genor Biopharma Holdings's total current assets for the quarter that ended in Dec. 2024 was HK$1,139.5 Mil.

Genor Biopharma Holdings Total Current Assets Historical Data

The historical data trend for Genor Biopharma Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings Total Current Assets Chart

Genor Biopharma Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

3,676.51

2,922.29

1,920.92

1,357.51

1,139.52

Genor Biopharma Holdings Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Current Assets	Get a 7-Day Free Trial							1,920.92	1,602.68	1,357.51	1,175.80	1,139.52

Genor Biopharma Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Genor Biopharma Holdings's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1130.441	+	-28.411	+	0	+	37.489
	=	1,139.5

Genor Biopharma Holdings's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1130.441	+	-28.411	+	0	+	37.489
	=	1,139.5

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Genor Biopharma Holdings (HKSE:06998) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Genor Biopharma Holdings's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1130.441	-	147.391	+	0.75 * 0	+	0.5 * 0
=	983.1

Genor Biopharma Holdings Total Current Assets Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

67N:Germany

Address

690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Executives

Forebright New Opportunities Fund, L.p.	2101 Beneficial owner
Forbright Global Limited	2201 Interest of corporation controlled by you
Fnof Gp Limited	2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh	2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd.	2101 Beneficial owner
Hsg Holding Limited	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p.	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p.	2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital I, L.p.	2101 Beneficial owner
Ni Xin	2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines